A review of montelukast in the treatment of asthma and allergic rhinitis

Bibliography

• NIMMAGGADDA SR, EVANS R 3RD: Allergy: etiology and epidemiology. Pediatr. Rev (1999) 20:111–115.
   PubMedGoogle Scholar
• TAYLOR WR, NEWACHECK PW: Impact of childhood asthma on health. Pediatrics (1992) 90:657–662.
   PubMed Web of Science ®Google Scholar
• NATHAN RA, MELTZER EO, SELNER JC, STORMS W: Prevalence of allergic rhinitis in the United States. Allergy Gin. Immunol. (1997) 99(SuppD:S808–S814.
   Google Scholar
• WRIGHT, AL, HOLBERG CJ, MARTINEZ FD, HALONEN M, MORGAN W, TAUSSIG LM: Epidemiology of physician-diagnosed allergic rhinitis in childhood. Pediatrics (1994) 94:895–901.
   PubMed Web of Science ®Google Scholar
• MCMENAMIN P: Costs of hay fever in the United States in 1990. Ann. Allergy (1994) 73:35–39.
   PubMedGoogle Scholar
• KAPSALI T, HOROWITZ E, DIOMER F, TOGIAS A: Rhinitis is ubiquitous in allergic asthmatics. I Allergy Gin. Immunol. (1997) 99:S138 (Abstract).
   Google Scholar
• HENDERSON WR JR: The role of leukotrienes in inflammation.Ann. Intern. Med. (1994) 121:684–697.
   PubMedGoogle Scholar
• CRETICOS PS, PETERS SP, ADKINSON NF JR et al.: Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl. Med. (1984) 310:1626–1630.
   Google Scholar
• WANG D, CLEMENT P, SMITZ J et al.: Concentrations of chemical mediators in nasal secretions after nasal allergen challenges in atopic patients. Eur: Arch. Otorhinolaryngol. Suppl. (1995) 1:S40–S43.
   Google Scholar
• OKUDA M, WATASE T, MEZAWA A et al.: The role of leukotriene D4 in allergic rhinitis. Ann. Allergy (1988) 60:537–540.
   PubMedGoogle Scholar
• KNAPP HR, MURRAY JJ: Leukotrienes as mediators of nasal inflammation. Adv. Prostaglandins Thromboxane Leukot. Res. (1994) 22:279–288.
   PubMedGoogle Scholar
• NACLERIO RIVI, BAROODY FM, TOGIAS AG: The role of leukotrienes in allergic rhinitis: a review. Am. Rev Respir: Dis. (1991) 143(5 pt 2):591–595.
   Google Scholar
• FERRERI NR, HOWLAND WC, STEVENSON DD et al.: Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am. Rev Respir. Dis. (1988) 137:847–854.
   PubMed Web of Science ®Google Scholar
• KOHI F, MIYAGAWA H, AGRAWAL DK et al.: Generation of leukotriene B4 and C4 from granulocytes of normal controls, allergic rhinitis, and asthmatic subjects. Ann. Allergy (1990) 65:228–232.
   PubMedGoogle Scholar
• JONES TR, LABELLE M, BELLEY M et al.: Pharmacology of montelukast sodium Can. .1 Physio. Pharmacol. (1995) 73:191–201.
   Google Scholar
• MURPHY R, HAMMARSTROM CS, SAMUELSSON B: Leukotriene C. A slow reacting substance from murine mastocytoma cells. Proc. Nati Acad. Sci USA (1979) 76:4275–4279.
   PubMed Web of Science ®Google Scholar
• DAHLEN S, HEDQVIST P,HAMMARSTROM S, SAMUELSSON S: Leukotrienes are potent constrictors of human bronchi. Nature (1980) 4;288(5790):484–486.
   Google Scholar
• BOUSQUET J, CHANEZ P,LACOSTE JY et al.: Eosinophilic inflammation in asthma. N Engl. I Med.(1990) 323:1033–1039.
   PubMed Web of Science ®Google Scholar
• FAHY JV, LIU J, WONG H,BOUSHEY HA: Cellular and biochemical analysis of induced sputum from asthmatic and from healthy patients. Am. RevRespir: Dis. (1993) 147:1126–1131.
   PubMed Web of Science ®Google Scholar
• GIBSON PG, GIRGIS-GABARDO A, MORRIS MM et al:Cellular characteristics of sputum from patients with asthma and chronic bronchitis. Thorax (1989) 44:693–699.
   PubMed Web of Science ®Google Scholar
• DJUKANOVIC R, ROCHE WR, WILSON JW et al.: State of the art: mucosal inflammation in asthma. Am. Rev Respir: Dis. (1990) 142:434–457.
   PubMed Web of Science ®Google Scholar
• SPADA CS, NIEVES AL, KRAUSS AHP, WOODWARD DF: Comparison of leukotriene B4 and D4 effects on human eosinophil and neutrophil motility in vitro.Leukoc. Biol. (1994) 55:183–191.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD DC, OSBORN RR, NEWSHOLME SJ, TORPHY TJ, HAY DWP: Persistent airway eosinophilia after leukotriene (LT) D4 administration in the guinea pig. Am.J. Respir: Crit. Care Med. (1996) 154:850–857.
   Google Scholar
• CHAN CC, MCKEE K, TAGARI P, CHEE P, FORD-HUTCHINSON A: Eosinophil-eicosanoid interactions: inhibition of eosinophil chemotaxis in vivo by a LTD4-receptor antagonist. Clin. Allergy (1990) 15:411–418.
   Google Scholar
• LAITINEN L, LAITINEN A, HAAHTELA T, SPUR B, VILKKA V, LEE TH: Leukotriene E4 and granulocyticinfiltration into asthmatic airways. Lancet (1993) 341:989–990.
   PubMed Web of Science ®Google Scholar
• DIAMANT Z, HILTERMAN JT, VAN RENSEN EL et al.: The effectof inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma.Am.Respir: Crit. Care Med. (1997)155:1247–1253.
   Google Scholar
• WENZEL SE, TRUDEAU JB,KAMINSKY DA, COHN J, MARTIN RJ, WESTCOTT JY: Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma.Am.Respir: Crit. Care Med. (1995)152:897–905.
   Google Scholar
• KANE GC, POLLICE M, KIM CJ et al.:A controlled trial of the effect of the 5-lipoxygenase inhibitor, zileuton, on lung inflammation produced by segmental antigen challenge in human beings. Allergy Clin. Immunol. (1996) 97:646–654.
   Google Scholar
• REISS TF, SORKNESS CA, STRICKERW et al.: Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic patients treated with and without inhaled corticosteroids. Thorax (1997) 52:45–48.
   PubMed Web of Science ®Google Scholar
• DELEPELEIRE I, REISS TF,ROCHETTE F et al.: Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Gin. Pharmacol. Ther.(1997) 61:83–92.
   Google Scholar
• NOONAN MJ, CHERVINSKY P, BRANDON M et al, FOR THE MONTELUKAST ASTHMA STUDY GROUP: Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Eur. Respir. (1998) 11:1232–1239.
   PubMed Web of Science ®Google Scholar
• REISS TF, CHERVINSKY P, DOCKHORN RJ, SHINGO S, SEIDENBERG B, EDWARDS TB, FOR THE MONTELUKAST CLINICAL RESEARCH STUDY GROUP: Montelukast, a once daily leukotriene receptor antagonist in the treatment of chronic asthma a multicenter, randomized, double-blind trial. Arch. Intern. Med. (1998) 158:1213–1220.
   PubMed Web of Science ®Google Scholar
• LEFF JA, BUSSEWW, PEARLMAN D et al.: Treatment of mild asthma and exercise-induced bronchoconstriction with montelukast, a leukotriene receptor antagonist. N Engl. Med. (1998) 339:147–152.
   PubMedGoogle Scholar
• PIZZICHINI E, PIZZICHINI MMM, EFTHIMIADIS A et al.: Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am. Respir. Grit. Care Med. (1996) 154:308–317.
   PubMed Web of Science ®Google Scholar
• CLAMAN DM, BOUSHEV HA, LIU J,WONG H, FAHY JV: Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic patients. I Allergy Clin. Immunol (1994) 94:861–869.
   PubMedGoogle Scholar
• GIBSON PG, HARGREAVE FE, GIRGIS-GABARDO A, MORRIS M, DENBURG JA, DOLOVICH J: Chronic cough with eosinophilic bronchitis: examination for variable airflow obstruction and response to corticosteroid. Clin. Exp. Allergy (1995) 25:127–132.
   PubMed Web of Science ®Google Scholar
• PIN I, GIBSON PG, KOLENDOWICZ R et al.: Use of induced sputum cell counts to investigate airway inflammation in asthma. Thorax (1992) 47:25–29.
   PubMed Web of Science ®Google Scholar
• PIZZICHINI E, PIZZICHINI MM, KIDNEY JC et al.: Induced sputum, bronchoalveolar lavage and blood from mild asthmatics: inflammatory cells, lymphocyte subsets and soluble markers compared. Eur. Respir J. (1998) 111:828–834.
   Google Scholar
• PIZZICHINI E, LEFF JA, REISS TF et al.:Montelukast reduces airway eosinophilic inflammation in asthma:a randomized,controlled trial. Eur. Respir. 1 (1999) 14:12-18.
   Google Scholar
• HARGREAVE FE, PIZZICHINI MMM, PIZZICHINI E: Assessment of airway inflammation. In: Asthma (Vol. 2).Barnes PJ, Grunstein MM, Leff J, Wooilcock A (Eds), Raven Press, New York, USA (1997):1433–1450.
   Google Scholar
• JARVIS B, MARKHAM A: Montelukast: a review of its therapeutic potential in persistent asthma. Drugs (2000) 59:891–928.
   PubMed Web of Science ®Google Scholar
• BJERMER L, BISGAARD H, BOUSQUET J et al.: Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. Br. Med. J. (2003) 327:1–6.
   PubMedGoogle Scholar
• MALMSTROM K, HAMPEL FC, PHILIP G, MALICE M-P, REISS TF, FOR THE MONTELUKAST SPRING RHINITIS INVESTIGATION GROUP: Montelukast in the treatment of spring allergic rhinitis in a large, double-blind, randomized, placebo-controlled study. J. Allergy Clin. Immunol (2001) 107:S157. (Abstract 519).
   Google Scholar
• MELTZER EO, MALMSTROM K, LU S et al.: Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: a randomized, placebo-controlledclinical trial. j Allergy Clin. Immunol(2000) 105:917–922.
   PubMed Web of Science ®Google Scholar
• NAYAK A, PHILIP G, LU S et al.: Efficacyand tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Allergy Asthma Immunol (2002) 88:592–600.
   PubMed Web of Science ®Google Scholar
• WILSON AM, ORR LC, SIMS EJ, LIP WORTH BJ: Effects of monotherapy with intra-nasal corticosteroid or combined oral histamine and leukotriene receptor antagonists in seasonal allergic rhinitis. Clin. Exp. Allergy (2001) 31:61–68.
   PubMed Web of Science ®Google Scholar
• http://www.lungusa.org/data/ data_102000.html AMERICAN LUNG ASSOCIATION: Prevalence based on revised National Health Interview Survey.Accessed March 6 (2001).
   Google Scholar